Consistently, lacidipine treatment or co‐administration with DOX/cisplatin significantly increased the mRNA expression of CCL5, CD274, CXCL10, and CXCL11 and decreased CCL2 mRNA levels in tumor tissues (Figure S4D–H, Supporting Information), thereby promoting immune cell infiltration and converting the “cold” into a “hot” tumor. The gene discussed is CCL5; the disease is neoplasm.